Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Cardiac repolarization and its relation to ventricular geometry and rate in reverse remodelling during antihypertensive therapy with irbesartan or atenolol: results from the SILVHIA study

Journal of Human Hypertension volume 21, pages 956–965 (2007)Cite this article

Abstract

Hypertensive left ventricular (LV) hypertrophy is associated with a substantial risk for malignant arrhythmias and sudden death. According to recent results, antihypertensive therapy with the angiotensin II type 1 receptor blocker irbesartan reverses both structural and electrical remodelling. However, the relation between the LV geometric pattern (concentric vs eccentric) and electrical reverse remodelling has not been characterized, neither has the relation between repolarization and rate (QT/RR and JT/RR relation), which presumably reflects the propensity for bradycardia-dependent ventricular arrhythmia. In this study, repeat echocardiographic and electrocardiographic measurements were performed in hypertensive patients with LV hypertrophy, randomized to double-blind therapy with irbesartan (n=44) or the β1-adrenoceptor blocker atenolol (n=48) for 48 weeks; 53 patients had concentric and 39 eccentric LV hypertrophy. In addition, 37 matched hypertensive subjects without LV hypertrophy and no current therapy served as controls. Irbesartan induced structural and electrophysiological reverse remodelling, independent of LV geometry. In contrast, atenolol had similar beneficial effect only in patients with concentric LV hypertrophy, while the response in those with eccentric hypertrophy was unfavourable with both prolonged repolarization time and an increased QT/RR slope (suggesting reverse-use dependence). In conclusion, there is a significant geometry-related difference in the reverse remodelling processes induced by irbesartan and atenolol. Echocardiographic characterization of the geometry in hypertension-induced LV hypertrophy might become an important step in the selection of optimal antihypertensive therapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Vakili BA, Okin PM, Devereux RB . Prognostic implications of left ventricular hypertrophy. Am Heart J 2001; 141: 334–341.

    Article  CAS  Google Scholar 

  2. Messerli FH . Hypertension and sudden cardiac death. Am J Hypertens 1999; 12: 181S–188S.

    Article  CAS  Google Scholar 

  3. Aronson R . Mechanisms of arrhythmias in ventricular hypertrophy. J Cardiovasc Electrophysiol 1991; 2: 249–261.

    Article  Google Scholar 

  4. Hart G . Cellular electrophysiology in cardiac hypertrophy and failure. Cardiovasc Res 1994; 28: 933–946.

    Article  CAS  Google Scholar 

  5. Pacifico A, Henry PD . Structural pathways and prevention of heart failure and sudden death. J Cardiovasc Electrophysiol 2003; 14: 764–775.

    Article  Google Scholar 

  6. Marbán E . Heart failure: the electrophysiologic connection. J Cardiovasc Electrophysiol 1999; 10: 1425–1428.

    Article  Google Scholar 

  7. Roden DM . Long QT syndrome: reduced repolarization reserve and the genetic link. J Intern Med 2006; 259: 59–69.

    Article  CAS  Google Scholar 

  8. Barr CS, Naas A, Freeman M, Lang CC, Struthers AD . QT dispersion and sudden unexpected death in chronic heart failure. Lancet 1994; 343: 327–329.

    Article  CAS  Google Scholar 

  9. Perkiomäki JS, Huikuri HV, Koistinen JM, Makikallio T, Castellanos A, Myerburg RJ . Heart rate variability and dispersion of QT interval in patients with vulnerability to ventricular tachycardia and ventricular fibrillation after previous myocardial infarction. J Am Coll Cardiol 1997; 30: 1331–1338.

    Article  Google Scholar 

  10. Sadanaga T, Ogawa S, Okada Y, Tsutsumi N, Iwanaga S, Yoshikawa T et al. Clinical evaluation of the use-dependent QRS prolongation and the reverse use-dependent QT prolongation of class I and class III antiarrhythmic agents and their value in predicting efficacy. Am Heart J 1993; 126: 114–121.

    Article  CAS  Google Scholar 

  11. Okada Y, Ogawa S, Sadanaga T, Mitamura H . Assessment of reverse use-dependent blocking actions of class III antiarrhythmic drugs by 24-h Holter electrocardiography. J Am Coll Cardiol 1996; 27: 84–89.

    Article  CAS  Google Scholar 

  12. Savelieva I, Yap YG, Yi G, Guo XH, Hnatkova K, Camm AJ et al. Relation of ventricular repolarization to cardiac cycle length in normal subjects, hypertrophic cardiomyopathy, and patients with myocardial infarction. Clin Cardiol 1999; 22: 649–654.

    Article  CAS  Google Scholar 

  13. Malmqvist K, Kahan T, Edner M, Held C, Hägg A, Lind L et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens 2001; 19: 1167–1176.

    Article  CAS  Google Scholar 

  14. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003.

    Article  Google Scholar 

  15. Karpanou EA, Vyssoulis GP, Psichogios A, Malakou C, Kyrozi EA, Cokkinos DV et al. Regression of left ventricular hypertrophy results in improvement of QT dispersion in patients with hypertension. Am Heart J 1998; 136: 765–768.

    Article  CAS  Google Scholar 

  16. Malmqvist K, Kahan T, Edner M, Bergfeldt L . Comparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish irbesartan left ventricular hypertrophy investigation versus atenolol (SILVHIA). Am J Cardiol 2002; 90: 1107–1112.

    Article  CAS  Google Scholar 

  17. Oikarinen L, Nieminen MS, Toivonen L, Viitasalo M, Wachtell K, Papademetriou V, et al., LIFE Study Investigators. Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint reduction (LIFE) study. Am Heart J 2003; 145: 919–925.

    Article  Google Scholar 

  18. Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB . Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994; 90: 1786–1793.

    Article  CAS  Google Scholar 

  19. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97: 48–54.

    Article  CAS  Google Scholar 

  20. Krumholz HM, Larson M, Levy D . Prognosis of left ventricular geometric patterns in the Framingham Heart Study. J Am Coll Cardiol 1995; 25: 879–884.

    Article  CAS  Google Scholar 

  21. Zabel M, Lichtlen PR, Haverich A, Franz MR . Comparison of ECG variables of dispersion of ventricular repolarization with direct myocardial repolarization measurements in the human heart. J Cardiovasc Electrophysiol 1998; 9: 1279–1284.

    Article  CAS  Google Scholar 

  22. Bergfeldt L, Melander H, Schenck-Gustafsson K . Time-dependent variation in the cardiac conduction system assessed in young healthy individuals at weeks' interval: implications for clinical trials. J Am Coll Cardiol 1991; 18: 792–800.

    Article  CAS  Google Scholar 

  23. Nowinski K, Bergfeldt L . The ‘normal’ response of the QT interval and QT dispersion following intravenous injection of the sodium-channel blocker disopyramide – methodological aspects. Cardiovasc Drugs Ther 1995; 9: 573–580.

    Article  CAS  Google Scholar 

  24. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH . Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114: 345–352.

    Article  CAS  Google Scholar 

  25. Muiesan ML, Salvetti M, Monteduro C, Bonzi B, Paini A, Viola S et al. Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients. Hypertension 2004; 43: 731–738.

    Article  CAS  Google Scholar 

  26. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I et al. Prognostic value of left ventricular mass and geometry in systemic hypertension with left ventricular hypertrophy. Am J Cardiol 1996; 78: 197–202.

    Article  CAS  Google Scholar 

  27. Silverman ME, Pressel MD, Brackett JC, Lauria SS, Gold MR, Gottlieb SS . Prognostic value of the signal-averaged electrocardiogram and a prolonged QRS in ischemic and nonischemic cardiomyopathy. Am J Cardiol 1995; 75: 460–464.

    Article  CAS  Google Scholar 

  28. Oikarinen L, Nieminen MS, Viitasalo M, Toivonen L, Wachtell K, Papademetriou V et al. Relation of QT interval and QT dispersion to echocardiographic left ventricular hypertrophy and geometric pattern in hypertensive patients. The LIFE study. The Losartan Intervention For Endpoint Reduction. J Hypertens 2001; 19: 1883–1891.

    Article  CAS  Google Scholar 

  29. Gavras I, Gavras H . The antiarrhythmic potential of angiotensin II antagonism: experience with losartan. Am J Hypertens 2000; 13: 512–517.

    Article  CAS  Google Scholar 

  30. De Mello WC . Cardiac arrhythmias: the possible role of the renin-angiotensin system. J Mol Med 2001; 79: 103–108.

    Article  CAS  Google Scholar 

  31. Emdad L, Uzzaman M, Takagishi Y, Honjo H, Uchida T, Severs NJ et al. Gap junction remodeling in hypertrophied left ventricles of aortic-banded rats: prevention by angiotensin II type 1 receptor blockade. J Mol Cell Cardiol 2001; 33: 219–231.

    Article  CAS  Google Scholar 

  32. Schwieler JH, Kahan T, Nussberger J, Hjemdahl P . Converting enzyme inhibition modulates sympathetic neurotransmission in vivo via multiple mechanisms. Am J Physiol 1993; 264: E631–E637.

    CAS  PubMed  Google Scholar 

  33. Brilla CG, Funck RC, Rupp H . Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000; 102: 1388–1393.

    Article  CAS  Google Scholar 

  34. Varo N, Etayo JC, Zalba G, Beaumont J, Iraburu MJ, Montiel C et al. Losartan inhibits the post-transcriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats. J Hypertens 1999; 17: 107–114.

    Article  CAS  Google Scholar 

  35. Gimelli A, Schneider-Eicke J, Neglia D, Sambuceti G, Giorgetti A, Bigalli G et al. Homogeneously reduced versus regionally impaired myocardial blood flow in hypertensive patients: two different patterns of myocardial perfusion associated with degree of hypertrophy. J Am Coll Cardiol 1998; 31: 366–373.

    Article  CAS  Google Scholar 

  36. Zabel M, Koller BS, Sachs F, Franz MR . Stretch-induced voltage changes in the isolated beating heart: importance of the timing of stretch and implications for stretch-activated ion channels. Cardiovasc Res 1996; 32: 120–130. Study. Lancet 2003;362: 619–620.

    Article  CAS  Google Scholar 

  37. Merri M, Moss AJ, Benhorin J, Locati EH, Alberti M, Badilini F . Relation between ventricular repolarization duration and cardiac cycle length during 24-h Holter recordings. Findings in normal patients and patients with long QT syndrome. Circulation 1992; 85: 1816–1821.

    Article  CAS  Google Scholar 

  38. Chevalier P, Burri H, Adeleine P, Kirkorian G, Lopez M, Leizorovicz A et al. QT dynamicity and sudden death after myocardial infarction: results of a long-term follow-up study. J Cardiovasc Electrophysiol 2003; 14: 227–233.

    Article  Google Scholar 

  39. Batchvarov VN, Ghuran A, Smetana P, Hnatkova K, Harries M, Dilaveris P et al. QT-RR relationship in healthy subjects exhibits substantial intersubject variability and high intrasubject stability. Am J Physiol Heart Circ Physiol 2002; 282: H2356–H2363.

    Article  CAS  Google Scholar 

  40. Franz MR, Zabel M . Electrophysiological basis of QT dispersion measurements. Progr Cardiovasc Dis 2000; 42: 311–324.

    Article  CAS  Google Scholar 

  41. Messerli FH, Grossman E, Goldbourt U . Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA 1998; 279: 1903–1907.

    Article  CAS  Google Scholar 

  42. Carlberg B, Samuelsson O, Lindholm LH . Atenolol in hypertension: is it a wise choice? Lancet 2004; 364: 1684–1689.

    Article  CAS  Google Scholar 

  43. Khan N, McAlister FA . Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ 2006; 174: 1737–1742.

    Article  Google Scholar 

  44. Lindholm LH, Dahlöf B, Edelman JE, Ibsen H, Borch-Johnsen K, Hecht Olsen M, et al., For the LIFE study group. Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. Lancet 2003; 362: 619–620.

    Article  CAS  Google Scholar 

  45. Aronow WS . Might losartan reduce sudden cardiac death in diabetic patients with hypertension? Lancet 2003; 362: 591–592.

    Article  Google Scholar 

Download references

Acknowledgements

The expert technical assistance by Marie-Louise O'Connor is greatly acknowledged. This study was supported by the Swedish Heart-Lung Foundation, Karolinska Institutet, Stockholm, Sweden; Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, USA; and Sanofi-Aventis, Paris, France.

Author information

Authors and Affiliations

  1. Division of Cardiovascular Medicine, Department of Clinical Sciences, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden

    K Malmqvist, T Kahan & M Edner

  2. Department of Molecular and Clinical Medicine/Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden

    L Bergfeldt

Authors
  1. K Malmqvist
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T Kahan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Edner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L Bergfeldt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T Kahan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Malmqvist, K., Kahan, T., Edner, M. et al. Cardiac repolarization and its relation to ventricular geometry and rate in reverse remodelling during antihypertensive therapy with irbesartan or atenolol: results from the SILVHIA study. J Hum Hypertens 21, 956–965 (2007). https://doi.org/10.1038/sj.jhh.1002250

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jhh.1002250

Keywords

This article is cited by

Search

Advanced search

Quick links